1932

Abstract

In the last 30 years, there have been many advances in the treatment of metastatic renal cell carcinoma of the clear cell type. Renal cell carcinoma has long been understood to have a component of immune mediation and has been responsive to immune-based therapies; in addition to early cytokine therapy, newer checkpoint inhibition therapies have also demonstrated activity. Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles of angiogenesis and hypoxic stress. This led to development of small-molecule tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin that have provided additional benefit to patients. Ongoing strategies of combinations of immune and antiangiogenic therapies may lead to further advancements.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-041916-124132
2018-01-29
2024-06-23
Loading full text...

Full text loading...

/deliver/fulltext/med/69/1/annurev-med-041916-124132.html?itemId=/content/journals/10.1146/annurev-med-041916-124132&mimeType=html&fmt=ahah

Literature Cited

  1. Siegel RL, Miller KD, Jemal A. 1.  2017. Cancer statistics, 2017. CA Cancer J. Clin. 67:7–30 [Google Scholar]
  2. Kovacs G, Akhtar M, Beckwith BJ. 2.  et al. 1997. The Heidelberg classification of renal cell tumours. J. Pathol. 183:131–33 [Google Scholar]
  3. Moch H, Cubilla AL, Humphrey PA. 3.  et al. 2016. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur. Urol. 70:93–105 [Google Scholar]
  4. Zbar B, Brauch H, Talmadge C, Linehan M. 4.  1997. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721–24 [Google Scholar]
  5. Latif F, Tory K, Gnarra J. 5.  et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–20 [Google Scholar]
  6. Hosoe S, Brauch H, Latif F. 6.  et al. 1990. Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8:634–40 [Google Scholar]
  7. Kaelin WG Jr. 7.  2008. The von Hippel-Lindau tumor suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8:865–73 [Google Scholar]
  8. Dalgliesh GL, Furge K, Greenman C. 8.  et al. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463:360–63 [Google Scholar]
  9. Creighton CJ, Morgan M, Gunaratne PH. 9.  et al. 2013. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43–49 [Google Scholar]
  10. Linehan W, Spellman PT, Creighton CJ. 10.  et al. 2016. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374:135–45 [Google Scholar]
  11. Toro JR, Nickerson ML, Wei MH. 11.  et al. 2003. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73:95–106 [Google Scholar]
  12. Everson TC, Cole WH. 12.  1956. Spontaneous regression of cancer: preliminary report. Ann. Surg. 144:366–80 [Google Scholar]
  13. Challis GB, Stam HJ. 13.  1990. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 29:545–50 [Google Scholar]
  14. Minasian LM, Motzer RJ, Gluck L. 14.  et al. 1993. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11:1368–75 [Google Scholar]
  15. Muss HB. 15.  1987. Interferon therapy for renal cell carcinoma. Semin. Oncol. 14:36–42 [Google Scholar]
  16. Fyfe G, Fisher RI, Rosenberg SA. 16.  et al. 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:688–96 [Google Scholar]
  17. Klapper JA, Downey SG, Smith FO. 17.  et al. 2008. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 113:293–301 [Google Scholar]
  18. Hamid O, Carvajal RD. 18.  2013. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin. Biol. Ther. 13:847–61 [Google Scholar]
  19. Choueiri TK, Fishman MN, Escudier B. 19.  et al. 2015. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with outcomes. J. Clin. Oncol. 33:S4500 (Abstr.) [Google Scholar]
  20. Motzer RJ, Escudier B, McDermott DF. 20.  et al. 2015. Nivolumab versus everolimus in advanced renal cell carcinoma. N. Engl. J. Med. 373:1803–13 [Google Scholar]
  21. McDermott DF, Drake CG, Sznol M. 21.  et al. 2015. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33:2013–20 [Google Scholar]
  22. McDermott DF, Sosman JA, Sznol M. 22.  et al. 2016. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34:833–42 [Google Scholar]
  23. Escudier B, Eisen T, Stadler WM. 23.  et al. 2007. Sorafenib in advanced clear-cell renal cell carcinoma. N. Engl. J. Med. 256:125–34 [Google Scholar]
  24. Bukowski RM, Eisen T, Stadler WM. 24.  et al. 2009. Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27:3312–16 [Google Scholar]
  25. Escudier B, Szczylik C, Hutson TE. 25.  et al. 2009. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27:1280–89 [Google Scholar]
  26. Motzer RJ, Hutson TE, Tomczak P. 26.  et al. 2007. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N. Engl. J. Med. 356:115–24 [Google Scholar]
  27. Sternberg CN, Davis ID, Mardiak J. 27.  et al. 2010. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28:1061–68 [Google Scholar]
  28. Motzer RJ, Hutson TE, Cella D. 28.  et al. 2013. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N. Engl. J. Med. 369:722–31 [Google Scholar]
  29. Choueiri TK, Halabi S, Sanford BL. 29.  et al. 2017. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J. Clin. Oncol. 35:591–97 [Google Scholar]
  30. Escudier B, Pluzanska A, Koralewski P. 30.  et al. 2007. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–11 [Google Scholar]
  31. Rini BI, Halabi S, Rosenberg JE. 31.  et al. 2010. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28:2137–43 [Google Scholar]
  32. Escudier B, Bellmunt J, Negrier S. 32.  et al. 2010. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28:2144–50 [Google Scholar]
  33. Rini BI, Rixe O, Bukowski RM. 33.  et al. 2005. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer. J. Clin. Oncol. 23:4509 (Abstr.) [Google Scholar]
  34. Rini BI, Escudier B, Tomczak P. 34.  et al. 2011. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–39 [Google Scholar]
  35. Matsuki M, Adachi Y, Ozawa Y. 35.  et al. 2017. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Cancer Sci 108:763–71 [Google Scholar]
  36. Motzer RJ, Hutson TE, Glen H. 36.  et al. 2015. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomized, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473–82 [Google Scholar]
  37. Choueiri TK, Escudier B, Powles T. 37.  et al. 2016. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917–27 [Google Scholar]
  38. Hudson CC, Liu M, Chiang GG. 38.  et al. 2002. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22:7004–14 [Google Scholar]
  39. Harding MW. 39.  2003. Immunophilins, mTOR, and pharmacodynamics strategies for a targeted cancer therapy. Clin. Cancer Res. 9:2882–86 [Google Scholar]
  40. Hudes G, Carducci M, Tomczak P. 40.  et al. 2007. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N. Engl. J. Med. 356:2271–81 [Google Scholar]
  41. Motzer RJ, Escudier B, Oudard S. 41.  et al. 2008. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–56 [Google Scholar]
  42. Motzer RJ, Escudier B, Oudard S. 42.  et al. 2010. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–66 [Google Scholar]
  43. Eichelberg C, Vervenne WL, De Santis M. 43.  et al. 2015. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitnib-sorafenib in the treatment of metastatic renal cell cancer. Eur. Urol. 68:837–47 [Google Scholar]
  44. Porta C, Procopio G, Carteni G. 44.  et al. 2011. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 108:E250–57 [Google Scholar]
  45. Motzer RJ, Barrios CH, Kim TM. 45.  et al. 2014. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32:2765–72 [Google Scholar]
  46. Nadal R, Amin A, Geynisman DM. 46.  et al. 2016. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann. Oncol. 27:1304–11 [Google Scholar]
  47. Finke JH, Rini BI, Ireland J. 47.  et al. 2008. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14:6674–82 [Google Scholar]
  48. Hipp MM, Hilf N, Walter S. 48.  et al. 2008. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111:5610–20 [Google Scholar]
  49. Rini BI, Stenzl A, Zdrojowy R. 49.  et al. 2016. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17:1599–1611 [Google Scholar]
  50. Amin A, Dudez AZ, Logan TF. 50.  et al. 2015. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J. Immunother. Cancer 3:14 [Google Scholar]
  51. 51. Argos Therapeutics. 2017. Independent data monitoring committee recommends discontinuation of the ADAPT phase 3 clinical trial of Rocapuldencel-T in metastatic renal cell carcinoma for futility following its planned interim data review. News release, Feb. 22
  52. Amin A, Plimack ER, Infante JR. 52.  et al. 2014. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 32:S5010 (Abstr.) [Google Scholar]
  53. McDermott DF, Atkins MB, Motzer RJ. 53.  et al. 2017. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). J. Clin. Oncol. 35:S6S, 431 (Abstr.) [Google Scholar]
  54. Hammers HJ, Plimack ER, Infante JR. 54.  et al. 2015. Expanded cohort results from CheckMate 016: a phase I study of nivolumab and ipilimumab in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 33:S4516 (Abstr.) [Google Scholar]
  55. Hammers HJ, Plimack ER, Sternberg C. 55.  et al. 2015. CheckMate 214: a phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 33:STPS4578 (Abstr.) [Google Scholar]
  56. Motzer RJ, Choueiri TK, Larkin J. 56.  et al. 2016. Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC). Ann. Oncol. 24:266–95 [Google Scholar]
/content/journals/10.1146/annurev-med-041916-124132
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error